The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed the day trading at $8.24 down -4.63% from the previous closing price of $8.64. In other words, the price has decreased by -$4.63 from its previous closing price. On the day, 2.26 million shares were traded.
Ratios:
For a better understanding of DNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.62 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when Che Austin bought 99 shares for $8.37 per share.
Che Austin bought 99 shares of DNA for $917 on Feb 27 ’25. On Feb 26 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $9.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.09 while its Price-to-Book (P/B) ratio in mrq is 0.59.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $64.40, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is -27.12%, while the 200-Day Moving Average is calculated to be -30.92%.
Shares Statistics:
A total of 42.70M shares are outstanding, with a floating share count of 36.99M. Insiders hold about 33.00% of the company’s shares, while institutions hold 58.55% stake in the company.
